Aneurysmal Bone Cyst (ABC): A Comprehensive Disease Characteristics Report

MONDO ID: MONDO:0018815 · Category: Locally aggressive USP6-rearranged bone neoplasm

Summary

Aneurysmal bone cyst (ABC) is a benign but locally aggressive, expansile osteolytic neoplasm of bone that predominantly affects children and young adults in the first two decades of life. It most commonly arises in the metaphysis of long bones (especially around the knee) and in the posterior elements of the vertebrae, and is defined histologically by blood-filled cystic spaces separated by fibrous septa containing bland spindle (myofibroblastic) cells, osteoclast-like multinucleated giant cells, and reactive woven bone. For most of the 20th century ABC was considered a reactive or vascular malformation of uncertain cause, but molecular cytogenetics has redefined the majority of cases as a true clonal neoplasm.

The central mechanistic insight, established over the past two decades, is that primary ABC (~70% of cases) is driven by somatic promoter-swap rearrangements of the USP6 gene (ubiquitin-specific protease 6, also called TRE2/TRE17, at 17p13.2). These rearrangements place the full-length USP6 coding sequence under the control of a constitutively active partner-gene promoter (classically CDH11, but now dozens of partners are known), driving USP6 overexpression. USP6 in turn activates NF-κB signaling to induce matrix metalloproteinases (MMP-9, MMP-10), promotes angiogenesis, and drives RANKL-mediated osteoclast recruitment — together producing the characteristic vascular, cystic, bone-destroying lesion. Crucially, the USP6 rearrangement is confined to the neoplastic myofibroblastic spindle cell and is absent in secondary ABC-like changes (~30% of cases) that arise within other bone tumors (e.g., giant cell tumor, chondroblastoma, fibrous dysplasia, osteosarcoma).

This molecular understanding has clinical consequences. USP6 FISH/RNA-sequencing is now used to confirm primary ABC and to distinguish it from mimics (including telangiectatic osteosarcoma). The NF-κB/RANKL axis provides a rationale for denosumab (anti-RANKL monoclonal antibody) as targeted systemic therapy, particularly for surgically challenging spinal/sacral lesions. Treatment remains dominated by curettage (± adjuvants) with recurrence rates of ~25–31%, but minimally invasive image-guided doxycycline sclerotherapy now achieves ~99% success with low morbidity. ABC does not metastasize and mortality is negligible; the principal adverse outcome is local recurrence, usually within 2 years.

Key Findings

Finding 1 — Primary ABC is a USP6-rearranged mesenchymal neoplasm, and the neoplastic cell is the myofibroblastic spindle cell

The landmark work of Oliveira and colleagues transformed the conceptual status of ABC from a reactive lesion to a bona fide neoplasm. Clonal chromosomal translocations at 17p13 were shown to place the USP6 (TRE2/TRE17) coding region under the control of the highly active CDH11 (osteoblast cadherin) promoter, producing a promoter-swap fusion that drives overexpression of full-length USP6 protein. In their series, USP6 and/or CDH11 rearrangements were detected in 36 of 52 (69%) primary ABCs.

Decisively, these rearrangements were restricted to the spindle (myofibroblastic) cells of the lesion and were not present in the multinucleated giant cells, inflammatory cells, endothelial cells, or osteoblasts — identifying the myofibroblastic spindle cell as the neoplastic cell of origin and framing the giant cells and vascular spaces as reactive/recruited secondary components (PMID: 15509545).

"USP6 and CDH11 rearrangements were restricted to spindle cells in the ABC and were not found in multinucleated giant cells, inflammatory cells, endothelial cells, or osteoblasts." — Oliveira et al.

This same study established that so-called secondary ABC — ABC-like cystic change occurring within another primary bone lesion — lacks the USP6 rearrangement (0/17 secondary ABCs), providing a molecular criterion that separates the two entities. A modern review reaffirms the proportions: primary ABC accounts for ~70% of cases and is a true neoplasm, whereas ABC-like (secondary) changes account for the remaining ~30% (PMID: 35941207).

"ABC, which accounts for approximately 70% of the cases, is now recognized to be a true neoplasm, whereas ABC-like changes associated to other bone neoplasms (also referred in the literature as secondary ABC) accounts for the remaining 30%." — Restrepo et al.

Fusion partner diversity. Although CDH11::USP6 is the classic fusion, the partner repertoire is broad and continues to expand. A morphomolecular study of 175 "USP6-associated neoplasms" (nodular fasciitis, myositis ossificans, ABC) found USP6 rearrangement in the great majority and identified 22 novel fusion partners, with the observation that the partner gene depends strongly on tumor morphology and anatomic location — supporting the idea that partner diversity may reflect the cell of origin (PMID: 41293881). Case reports and small series document a growing list of ABC partners including FAT1::USP6 and MIR22HG::USP6 in solid-variant craniofacial ABC (PMID: 35102523), AHNAK::USP6 in polyostotic solid-variant vertebral ABC (PMID: 35717456), PAFAH1B1::USP6 (chromothripsis-induced) in periosteal solid ABC (PMID: 38979775), FGFR1::USP6 in orbital ABC (PMID: 36356178), and SEC24D::USP6, HNRNPC::USP6, and ERRFI1::USP6 in pediatric long-bone ABC (PMID: 41432301). All converge on a single functional outcome: transcriptional upregulation of full-length USP6.

Finding 2 — USP6 drives tumorigenesis via NF-κB-mediated matrix metalloproteinase production

The functional mechanism linking USP6 overexpression to the ABC phenotype was defined experimentally by Ye and colleagues. Overexpression of TRE17/USP6 is sufficient to induce expression of MMP-9 and MMP-10, in a manner that requires the enzyme's ubiquitin-specific protease (USP/deubiquitinase) catalytic activity but not its ability to bind the small GTPase Arf6. Mechanistically, USP6 induces MMP-9 transcription through activation of NF-κB, mediated in part by the GTPase RhoA and its effector kinase ROCK (PMID: 20418905).

"TRE17 is sufficient to induce expression of MMP-9 and MMP-10, in a manner requiring its USP activity, but not its ability to bind Arf6. TRE17 induces transcription of MMP-9 through activation of nuclear factor-kappaB (NF-kappaB), mediated in part by the GTPase RhoA and its effector kinase, ROCK." — Ye et al.

Critically, xenografts of TRE17-expressing cells formed vascularized tumors that reproduced key features of ABC, and tumorigenesis was dependent on the intact USP catalytic domain. This provides direct causal evidence that USP6's deubiquitinase activity — not merely its overexpression as a bystander — drives the matrix-degrading, angiogenic, osteolytic program that defines the lesion.

Finding 3 — Recurrence rates are modality-dependent, and minimally invasive sclerotherapy rivals surgery

ABC is non-metastatic and rarely fatal, so the dominant clinical outcome measure is local recurrence, which typically occurs within 2 years of treatment. Recurrence varies substantially by treatment modality:

"The standard of care cure for ABC has been curettage with or without bone grafting of the defect but is burdened by recurrence rates of approximately 25%-31%." — Cevolani et al. (PMID: 37638388)

"Of the 77 lesions, 76 (99%) were successfully treated. Twelve lesions (16%) recurred but resolved with additional doxycycline treatment." — Wong et al. (PMID: 39265785)

"The recurrence rate was 50% (4/8 patients) with the traditional technique (group 1) and 19% (4/21) in the 4-step technique (group 2)." — Grigoriou et al. (PMID: 32986586)

The takeaway is that aggressive local control — whether by adjuvant-augmented curettage (burr, electrocautery, phenol) or by percutaneous sclerotherapy — substantially reduces recurrence relative to simple curettage, and minimally invasive doxycycline sclerotherapy has emerged as a highly effective, low-morbidity alternative to open surgery, particularly at anatomically difficult sites.

Detailed Section-by-Section Report

1. Disease Information

Overview. Aneurysmal bone cyst is a benign, locally aggressive, expansile, osteolytic bone tumor characterized by blood-filled cystic spaces separated by fibrous septa containing myofibroblastic spindle cells, osteoclast-like giant cells, and reactive bone. Despite the name, it is neither an aneurysm nor a simple cyst; primary ABC is a clonal neoplasm. Lesions can grow rapidly and cause pain, swelling, pathologic fracture, and (in the spine) neurologic compromise (PMID: 22474093; PMID: 35941207).

Key identifiers. - MONDO: MONDO:0018815 - ICD-O: 9260/0 (aneurysmal bone cyst) - ICD-10: M85.5 (aneurysmal bone cyst); ICD-11: relevant benign bone neoplasm code - MeSH: "Bone Cysts, Aneurysmal" (D017824) - Orphanet: relevant rare bone tumor entry - Causal gene: USP6 (HGNC:12629; NCBI Gene 9098; OMIM *604334; locus 17p13.2)

Synonyms / alternative names. Aneurysmal bone cyst; ABC; primary aneurysmal bone cyst; solid variant of ABC (SVABC); giant cell reparative granuloma (historical term for some jaw lesions). "USP6-associated neoplasm" is the broader molecular family (with nodular fasciitis and myositis ossificans).

Data provenance. Information here is derived from aggregated disease-level resources — pathology case series, molecular cytogenetic studies, treatment cohorts, and review articles — not from individual EHR-derived patient records.

2. Etiology

Primary cause (genetic, somatic). Primary ABC is caused by a somatic clonal rearrangement of USP6, a promoter-swap event that drives overexpression of full-length USP6 protein (PMID: 15509545; PMID: 35941207). This is an acquired somatic event confined to lesional tissue — not inherited and not present in the germline.

Secondary ABC. ~30% of ABC-like lesions are secondary: cystic, blood-filled change superimposed on a pre-existing bone lesion (giant cell tumor of bone, chondroblastoma, fibrous dysplasia, osteoblastoma, osteosarcoma). These lack USP6 rearrangement and are driven by the underlying primary lesion (PMID: 15509545).

Risk factors. - Genetic: No inherited susceptibility loci or germline risk variants are established. The driver is a somatic structural rearrangement acquired in a single myofibroblastic clone. - Environmental / demographic: Young age (first two decades) is the dominant demographic risk factor. A history of trauma has long been anecdotally associated, and older "vascular/traumatic" hypotheses invoked a local hemodynamic disturbance, but these remain unproven and are now largely superseded by the neoplastic (USP6) model (PMID: 22474093).

Protective factors. None established (genetic or environmental).

Gene–environment interactions. No validated gene–environment interaction is described. The disease is initiated by a stochastic somatic rearrangement; environmental modulation of that event is not characterized.

3. Phenotypes

Onset: childhood/adolescence predominant. Severity: variable — from incidental to severely destructive. Progression: often rapidly progressive/expansile; can be episodic with growth spurts. Frequency: pain and swelling are the most common presentations across series (PMID: 22474093; PMID: 18761766).

Quality of life. After appropriate surgical treatment, functional outcomes are generally good. In pediatric pelvic ABC treated with extended curettage and grafting, mean Toronto Extremity Salvage Score (TESS) was 95, MSTS'93 was 93%, and SF-36 self-rated general health was 87% of maximum at ~11 years follow-up (PMID: 24817630). Suggested QoL tools: SF-36, MSTS'93, TESS.

4. Genetic / Molecular Information

Causal gene. USP6 (ubiquitin-specific peptidase 6; aliases TRE2, TRE17; HGNC:12629; OMIM 604334; locus 17p13.2). ABC is defined by structural rearrangement of USP6*, not point mutation.

Variant type / class. The pathogenic event is a balanced (or complex) chromosomal translocation / gene fusion — a promoter-swap in which the USP6 coding sequence is juxtaposed to a partner-gene promoter/enhancer, driving overexpression of full-length USP6. It is a gain-of-function mechanism (overexpression of intact protein), distinct from missense/frameshift point mutations.

Fusion partners. CDH11::USP6 is classic. Documented and novel partners include MYH9 (common in nodular fasciitis), FAT1, MIR22HG, AHNAK, PAFAH1B1, FGFR1, SEC24D, HNRNPC, ERRFI1, and ≥22 additional partners reported in USP6-associated neoplasms (PMID: 41293881; PMID: 35102523; PMID: 35717456; PMID: 38979775; PMID: 41432301).

Somatic vs germline. Somatic — clonal, lesion-restricted; not heritable. Classification: the USP6 rearrangement is a diagnostic, pathogenic somatic driver (COSMIC/somatic domain; not an ACMG germline classification).

Allele frequency. Not applicable — a somatic structural event, absent from population germline databases (gnomAD, 1000 Genomes).

Functional consequence. Gain of function through overexpression of catalytically active USP6 deubiquitinase, activating downstream NF-κB and matrix-degrading programs (PMID: 20418905).

Chromosomal abnormalities. 17p13 translocations; in at least one reported case, USP6 rearrangement was generated by chromothripsis (PAFAH1B1::USP6), producing a solid periosteal ABC initially mistaken for osteosarcoma (PMID: 38979775).

Modifier genes / epigenetics. Not established for ABC.

5. Environmental Information

No validated environmental etiologic agents. Trauma has been historically proposed as a trigger but is unproven and not required for the USP6-driven neoplastic model (PMID: 22474093). Lifestyle factors: none established. Infectious agents: none — ABC is not an infectious disease.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation):

1. A somatic chromosomal rearrangement at 17p13.2 juxtaposes the USP6 coding sequence to an active partner-gene promoter (e.g., CDH11) in a single myofibroblastic spindle cell → results in clonal overexpression of full-length USP6 protein. (Demonstrated — Oliveira 2004, PMID 15509545.)
2. Overexpressed USP6, via its ubiquitin-specific protease (deubiquitinase) activity, → activates the RhoA–ROCK pathway and NF-κB signaling. (Demonstrated — Ye 2010, PMID 20418905.)
3. NF-κB activation → induces transcription of matrix metalloproteinases MMP-9 and MMP-10 (and other targets). (Demonstrated — Ye 2010.)
4. MMP-mediated extracellular-matrix degradation, together with USP6-driven pro-angiogenic signaling, → leads to local matrix remodeling and formation of the vascular, blood-filled cystic spaces characteristic of ABC. (Demonstrated in xenograft; USP-domain-dependent.)
5. The neoplastic myofibroblasts and lesional stroma → produce RANKL, which → recruits and activates osteoclast-like multinucleated giant cells. (Inferred from ABC/GCT biology and denosumab response — not fully proven in ABC.)
6. RANKL-driven osteoclastic activity → results in progressive osteolysis, cortical expansion and thinning → leads to the clinical manifestations: pain, swelling, pathologic fracture, and (site-dependent) neurologic or ophthalmic compromise. (Demonstrated clinically/radiographically.)

Branch point: at steps 5–6 the mechanism converges on the RANK/RANKL/osteoclast axis, which is the pharmacologic target of denosumab; devascularization and calcification on denosumab therapy support this branch (PMID: 26730528; PMID: 36282899).

Molecular pathways: NF-κB signaling (KEGG hsa04064), RhoA/ROCK; RANK–RANKL–OPG axis; ubiquitin-proteasome/deubiquitination. Cellular processes (GO): extracellular matrix disassembly (GO:0022617), positive regulation of NF-κB transcription factor activity (GO:0051092), osteoclast differentiation (GO:0030316), angiogenesis (GO:0001525), bone resorption (GO:0045453). Protein dysfunction: gain of function via USP6 deubiquitinase overexpression. Immune/inflammatory: NF-κB-driven inflammatory milieu and osteoclast recruitment. Tissue damage: MMP-mediated matrix degradation and osteoclastic bone resorption.

Cell types (CL): neoplastic myofibroblast (CL:0000186 / fibroblast CL:0000057); reactive osteoclast (CL:0000092); endothelial cell (CL:0000115, reactive); osteoblast (CL:0000062, reactive). Molecular profiling: whole-transcriptome RNA-sequencing is the most informative modality and now routinely detects USP6 fusions and identifies novel partners (PMID: 41432301; PMID: 41293881).

7. Anatomical Structures Affected

• Organ / system level: skeletal system (musculoskeletal). Primary structure = bone (UBERON:0002481, bone tissue; UBERON:0001474, bone element). Secondary involvement by mass effect: spinal cord/nerve roots (spinal ABC), orbit/eye (orbital ABC), paranasal sinuses and jaw (craniofacial ABC).
• Common sites: metaphysis of long bones — especially about the knee (distal femur UBERON:0002862, proximal tibia); also humerus, pelvis, and posterior elements of vertebrae (UBERON:0002412) (PMID: 22474093; PMID: 35941207).
• Uncommon sites: mandible/maxilla (PMID: 18761766; PMID: 16609883), orbit (PMID: 36356178), skull base, and other flat/craniofacial bones (often solid variant).
• Tissue level: connective tissue / bone; fibrous septa with myofibroblasts. Subcellular (GO CC): cytoplasm (GO:0005737), nucleus (GO:0005634, site of NF-κB action); extracellular region/matrix (GO:0005576) for secreted MMPs.
• Localization / lateralization: usually solitary and unilateral / monostotic; rare polyostotic and synchronous presentations are reported (e.g., multi-vertebral solid variant, PMID: 35717456).

8. Temporal Development

• Onset: predominantly pediatric/adolescent (first two decades); can occur in young adults. Onset is typically subacute to chronic with progressive pain and swelling; occasionally acute presentation via pathologic fracture (PMID: 22474093).
• Progression: locally aggressive and often rapidly expansile, but benign (non-metastasizing). No formal malignant staging applies.
• Disease course: effectively curable with adequate local control; the natural risk is local recurrence, usually within 2 years (PMID: 36356178).
• Remission: achieved by treatment (surgery, sclerotherapy, denosumab). Rare spontaneous regression is described but not the norm. Critical window: recurrence surveillance is most important in the first 2 years post-treatment.

9. Inheritance and Population

• Epidemiology: ABC is rare, comprising roughly 1–2% of primary bone tumors; commonly cited incidence is on the order of ~0.1–0.15 per 100,000/year. Peak incidence in the first two decades of life (PMID: 22474093; PMID: 35941207).
• Inheritance: not inherited. The driver is a somatic USP6 rearrangement; there is no Mendelian inheritance pattern, no penetrance/expressivity, no anticipation, no founder effect, and no carrier frequency to report.
• Sex ratio: approximately equal, with a slight female predominance in some series.
• Age distribution: heavily skewed toward children and adolescents.
• Geographic distribution: no defined endemic distribution; occurs worldwide.

10. Diagnostics

Imaging. Radiography shows an eccentric, expansile, radiolucent (lytic) metaphyseal lesion with cortical thinning. MRI classically demonstrates fluid-fluid levels from layering of blood components — a hallmark but not pathognomonic feature (also seen in telangiectatic osteosarcoma). CT delineates cortical integrity (PMID: 22474093; PMID: 30413280). RadLex/Radiopaedia are relevant imaging references.

Histopathology / biopsy. Blood-filled cystic spaces separated by fibrous septa containing bland spindle (myofibroblastic) cells, osteoclast-like multinucleated giant cells, and reactive woven bone; myofibroblastic cells are smooth-muscle-actin (SMA) positive (PMID: 41432301). The solid variant lacks prominent cystic spaces and can closely mimic other tumors (PMID: 30413280; PMID: 35102523).

Molecular (definitive). USP6 FISH (break-apart) and targeted RNA-sequencing / NGS detect the USP6 rearrangement and confirm primary ABC, distinguishing it from secondary ABC-like change and from mimics. RNA-seq is especially valuable in solid variants and unusual locations where FISH may miss atypical fusions (PMID: 15509545; PMID: 35102523; PMID: 41432301). Nanopore/long-read DNA sequencing can resolve complex rearrangements (e.g., chromothripsis-generated fusions) (PMID: 38979775).

Differential diagnosis. Telangiectatic osteosarcoma (critical malignant mimic), giant cell tumor of bone, unicameral (simple) bone cyst, chondroblastoma with ABC-like change, fibrous dysplasia, osteoblastoma; solid-variant ABC additionally mimics Ewing sarcoma, Langerhans cell histiocytosis, and metastasis. USP6 status is the key molecular discriminator for primary ABC (PMID: 35102523; PMID: 22474093).

Screening: none — ABC is somatic, non-heritable, and sporadic; population/genetic screening is not applicable.

11. Outcome / Prognosis

• Survival / mortality: ABC is benign and does not metastasize; disease-specific mortality is negligible. Life expectancy is normal.
• Morbidity: driven by local destruction — pain, pathologic fracture, growth disturbance (when the physis/triradiate cartilage is involved), and neurologic/ophthalmic deficits at spinal/orbital sites. With modern treatment, functional outcomes are generally excellent (TESS 95, MSTS 93% in pediatric pelvic ABC; PMID: 24817630).
• Principal adverse outcome — recurrence: ~25–31% after simple curettage, reduced with adjuvants or sclerotherapy (see Finding 3). Recurrences usually manifest within 2 years (PMID: 37638388; PMID: 36356178).
• Prognostic factors: anatomic site (spine, pelvis, juxta-articular = higher morbidity and technical difficulty), completeness of local control/resection, and lesion size. Molecular prognostic biomarkers beyond the diagnostic USP6 fusion are not established.

12. Treatment

Surgical / interventional (mainstay). - Intralesional curettage ± bone grafting — standard of care; recurrence ~25–31% (PMID: 37638388). NCIT: Curettage; Bone Graft. - Extended/adjuvant curettage — high-speed burr, electrocautery, phenol, cryotherapy reduce recurrence (e.g., 4-step spinal technique: 19% vs 50%; PMID: 32986586; pediatric pelvic extended curettage with excellent outcomes, PMID: 24817630; femoral head/neck salvage, PMID: 29416170). - En bloc resection / reconstruction — for aggressive or recurrent lesions; Ilizarov bone transport for large defects (PMID: 39600861); avascular/vascular bone grafting (PMID: 28463677). - Selective arterial embolization — as adjunct or primary therapy, especially for hypervascular spinal lesions (PMID: 37638388).

Minimally invasive / percutaneous. - Image-guided doxycycline sclerotherapy — 99% ultimate success, 16% recurrence resolved with repeat treatment; effective for appendicular, pelvic, mandibular, and recurrent lesions (PMID: 39265785; PMID: 39311568; PMID: 39637081). CHEBI: doxycycline (CHEBI:50845). - Percutaneous cryoablation ± protective doxycycline sclerotherapy — for lesions near critical neurovascular structures (PMID: 38567007). - Modified single-session sclerograft (doxycycline ± cryoablation + regenerative grafting) — 25.9% reintervention (PMID: 42477120). - Osteoconductive cement injection (e.g., Cerament) for select spinal lesions (PMID: 24186854).

Pharmacotherapy / targeted (mechanism-based). - Denosumab — human monoclonal anti-RANKL antibody. Targets the RANK/RANKL osteoclast axis implicated in ABC bone destruction. Produces symptomatic relief, calcification, size reduction, and devascularization; used as rescue therapy for recurrent/unresectable disease and as neoadjuvant to enable safer resection of spinal ABC (PMID: 26730528; PMID: 36282899; PMID: 27244112; scoping review PMID: 39445490). NCIT: Denosumab (C2724). Caution: rebound and long-term efficacy after cessation remain under study.

"The bone destruction in both giant cell tumors of bone and ABCs is mediated by RANK ligand (RANKL) produced by the tumor cells. Denosumab, a human monoclonal antibody to RANKL, is effective in the treatment of giant cell tumors of bone." — PMID: 26730528

Treatment strategy. Choice depends on site, size, and aggressiveness. Long-bone/appendicular lesions: curettage + adjuvant or doxycycline sclerotherapy. Spinal/sacral/pelvic lesions: embolization, extended curettage, and/or neoadjuvant denosumab to reduce vascularity and morbidity. Orbital/craniofacial: surgery, embolization, and RANKL inhibition (PMID: 36356178).

13. Prevention

No primary prevention exists — ABC arises from a sporadic somatic rearrangement with no known modifiable risk factors and no infectious or hereditary basis. Secondary/tertiary prevention focuses on early diagnosis and complete local control to prevent recurrence and complications: aggressive adjuvant curettage, sclerotherapy, and post-treatment imaging surveillance (particularly within 2 years). Genetic counseling, carrier/prenatal screening, immunization, and public-health interventions are not applicable.

14. Other Species / Natural Disease

• Taxonomy / natural disease: Aneurysmal bone cysts occur naturally in domestic animals (notably horses, Equus caballus, NCBI Taxon 9796; and dogs, Canis lupus familiaris, NCBI Taxon 9615), where they present as expansile, blood-filled osteolytic bone lesions analogous to the human disease (veterinary/OMIA literature). Detailed molecular (USP6) characterization in animals is limited.
• Orthology: USP6 is notable as a primate-specific/hominoid gene that arose via a chimeric duplication event; a true one-to-one rodent ortholog is lacking, which constrains conventional mouse modeling (see Section 15).
• Zoonosis: not applicable — ABC is neoplastic, not transmissible.

15. Model Organisms

• Xenograft / cell models (primary evidence): Overexpression of TRE17/USP6 in cultured cells and xenograft tumors recapitulates key ABC features — vascularized, matrix-degrading tumor formation dependent on the USP catalytic domain and NF-κB activation (PMID: 20418905). This in vitro/xenograft system is the principal functional model of ABC pathogenesis.
• Genetic engineering: transgenic/inducible USP6-overexpression constructs are used to study downstream signaling (NF-κB, MMP-9/10, RhoA-ROCK).
• Limitation: because USP6 is essentially primate-specific and acts through a promoter-swap overexpression mechanism, standard rodent knockout models do not naturally reproduce the disease; models rely on forced human USP6 overexpression rather than endogenous orthologous mutation. This is a recognized gap.
• Applications: these models establish causality of the USP6→NF-κB→MMP axis and provide a platform to test USP6-deubiquitinase inhibitors, NF-κB inhibitors, and RANKL-targeted agents.

Mechanistic Model / Interpretation

  Somatic 17p13.2 rearrangement (promoter swap)
  e.g. CDH11 / MYH9 / FAT1 / AHNAK / PAFAH1B1 / FGFR1 promoter  ──►  USP6 (full-length)
        │  (in myofibroblastic SPINDLE cell only — the neoplastic cell)
        ▼
     USP6 overexpression  (gain of function; requires deubiquitinase/USP activity)
        │
     ┌──────────┴───────────┐
     ▼                      ▼
     RhoA / ROCK              NF-κB activation
     └──────────┬───────────┘
        ▼
Transcription of MMP-9 / MMP-10  +  pro-angiogenic signaling
        │
        ▼
   ECM degradation → blood-filled cystic vascular spaces (aneurysmal architecture)
        │
        ▼
     Lesional RANKL production  ──►  recruitment/activation of osteoclast-like GIANT CELLS
        │                         │
        ▼                         ▼
      Osteoclastic bone resorption → OSTEOLYSIS, cortical expansion/thinning
        │
        ▼
   CLINICAL: pain, swelling, pathologic fracture, neurologic/ophthalmic compromise

      Targeted intervention points:
• RANKL  ──► DENOSUMAB (blocks osteoclast axis; devascularization/calcification)
• Cyst cavity ──► DOXYCYCLINE sclerotherapy (also an MMP inhibitor) / cryoablation
• Whole lesion ──► curettage + adjuvants / embolization / resection

Two features of this model are worth emphasizing for a knowledge base. First, the single-cell specificity of the driver — USP6 rearrangement occurs only in the myofibroblastic spindle cell — reframes the giant cells and vascular spaces as reactive, recruited components downstream of a myofibroblast-intrinsic oncogenic program. Second, the model unifies diagnosis and therapy: the same USP6 lesion that defines primary ABC molecularly (FISH/RNA-seq) sits upstream of the RANKL axis that denosumab targets and the MMP/matrix program that doxycycline sclerotherapy disrupts (doxycycline is itself a known MMP inhibitor, an appealing mechanistic congruence).

Evidence Base

Evidence source types: human clinical/pathology series (majority); in vitro + xenograft functional biology (PMID: 20418905); molecular cytogenetics (PMID: 15509545) and NGS/RNA-seq case series.

Limitations and Knowledge Gaps

1. No native animal genetic model. USP6 is primate/hominoid-specific, so there is no straightforward orthologous rodent knock-in; mechanistic data derive from human-USP6 overexpression and xenografts rather than an endogenous-mutation animal model.
2. RANKL step is inferred, not fully proven in ABC. The osteoclast/RANKL branch is strongly supported by denosumab response and analogy to giant cell tumor, but a direct, quantitative demonstration that USP6-driven myofibroblasts produce RANKL to recruit ABC giant cells is less rigorously established than the upstream USP6→NF-κB→MMP steps.
3. Denosumab durability unknown. Reported responses are largely from case reports/small series; rebound after discontinuation, optimal duration, and long-term recurrence are not well quantified.
4. Secondary ABC pathophysiology. The ~30% of ABC-like lesions lack USP6 and are mechanistically heterogeneous (driven by the host lesion); their biology is under-characterized in this report.
5. Epidemiology precision. Prevalence/incidence figures are approximate; ABC is rare and under-registered, and no large population registry estimate was independently derived here.
6. Fusion-partner functional consequences. Whether different partners (beyond driving overexpression) confer distinct clinical behavior (e.g., solid variant, site, recurrence) is an open question raised by the partner-diversity literature.
7. Genotype–phenotype/prognostic biomarkers. Beyond the diagnostic USP6 fusion, no validated molecular prognostic markers stratify recurrence risk.

Proposed Follow-up Experiments / Actions

1. Quantify RANKL in USP6-driven ABC — measure RANKL/OPG expression in laser-capture-microdissected spindle cells vs giant cells to close the inferential gap in the osteoclast branch; correlate with denosumab response.
2. Prospective denosumab trial with defined stopping rules — track rebound, radiographic recurrence, and time-to-recurrence after cessation across anatomic sites, especially spine/sacrum.
3. Partner-stratified outcome study — pool RNA-seq-characterized ABCs to test whether specific USP6 partners (e.g., FGFR1, AHNAK, chromothriptic fusions) associate with solid variant, atypical sites, or recurrence risk.
4. Head-to-head modality comparison — prospective/registry comparison of doxycycline sclerotherapy vs adjuvant curettage vs denosumab for matched lesions, with recurrence and QoL (TESS/MSTS/SF-36) endpoints.
5. Target the USP6 deubiquitinase — screen USP6 catalytic-domain inhibitors in the TRE17 xenograft model, exploiting the demonstrated dependence of tumorigenesis on USP activity.
6. Standardize molecular diagnostics — adopt reflex RNA-seq (not FISH alone) for solid-variant and atypically located lesions to capture non-classical fusions and avoid misdiagnosis as osteosarcoma.
7. Build a longitudinal ABC registry to firm up incidence, sex ratio, site distribution, and recurrence timelines with modern molecular confirmation.

Report compiled from molecular cytogenetic, functional, and clinical literature (33 papers reviewed; 3 confirmed findings). Evidence is predominantly human clinical/pathological with supporting in vitro/xenograft functional data. ABC is benign and non-metastatic; the dominant clinical concern is local recurrence, and the unifying biology is somatic USP6 overexpression driving an NF-κB/MMP/RANKL osteolytic program in myofibroblastic spindle cells.

Artifacts

• OpenScientist final report
• OpenScientist final report

Citations

1. PMID:15509545
2. PMID:35941207
3. PMID:41293881
4. PMID:35102523
5. PMID:35717456
6. PMID:38979775
7. PMID:36356178
8. PMID:41432301
9. PMID:20418905
10. PMID:37638388
11. PMID:39265785
12. PMID:42477120
13. PMID:32986586
14. PMID:22474093
15. PMID:18761766
16. PMID:24817630
17. PMID:26730528
18. PMID:36282899
19. PMID:16609883
20. PMID:30413280
21. PMID:29416170
22. PMID:39600861
23. PMID:28463677
24. PMID:39311568
25. PMID:39637081
26. PMID:38567007
27. PMID:24186854
28. PMID:27244112
29. PMID:39445490